PW01-005 – Effects of placebo and colchicine on FMF patients by unknown
MEETING ABSTRACT Open Access
PW01-005 – Effects of placebo and colchicine on
FMF patients
F Özaltın1, Y Bilginer1, B Gülhan1*, I Bajin1, Ö Erdoğan2, S Özen1
From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Lausanne, Switerland. 22-26 May 2013
Introduction
The diagnosis of Familial Mediterranean fever (FMF) is
basically a clinical one although genetic confirmation is of
great help to the clinician. A response to colchicine has
been suggested as a diagnostic criterion.
Objectives
The placebo effect of a drug has never been assessed on
FMF diagnosis. We aimed to assess this effect in children.
Methods
Patients who fulfilled the pediatric criteria for the diagno-
sis of FMF were included in this study. Demographic and
clinical features (attack frequency, features of each attack,
etc) were recorded. In first part of the study, patients
were randomized in two treatment groups (colchicine
and placebo) double blind, with a cross-over study design
in 3 months duration.
Results
A total amount of 50 patients (22 girls, 28 boys) were
included. The median age of the patients was 8.5 years
(2.5-17.5). 78% of the patients suffered from fever attacks
suggestive of FMF every 1-4 weeks. The attack interval of
the remaining patients was more than one month. At the
time of admission, the median values for ESR and CRP
were; 24.5 mm/hr (1-100) and 2 mg/dl (0-31), respectively.
Half of the patients (n=25) were randomized to colchicine
and the other half (n=25) to placebo. At the unblind
period the results were assessed: patients treated with
colchicine had lower ESR when compared to placebo in
the first phase only (p=0.004). CRP, WBC and SAA levels
were not statistically different neither in the first phase
nor after the cross-over period. However, the number of
attacks were significantly less in the colchicine group
(median 0 attack) when compared to the placebo group
(median 1 attack) (p=0.011).
In the study group, 13 patients were homozygous, 11
patients were compound heterozygous and seven patients
were heterozygous for MEFV mutation. The rest of the
patients (38%) did not carry any MEFV mutations.
Conclusion
The number of attacks were less in the colchicine group
however, the lack of difference in the laboratory para-
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